MedTrace Logo

Effect of Modulating Gamma Oscillations Using tACS

NCT03412604 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-08-22

Study results available
· View outcomes & findings →

Summary

This study aims to implement an intervention based on multiple, individualized multifocal tACS stimulation sessions based on individual PET and MRI information in patients with amyloid-positive PET with the hope that this leads to microglia activation and decrease in cerebral amyloid and tau depositions in human patients with AD.

Conditions

  • Alzheimer Disease

Interventions

DEVICE

Transcranial Alternating Current Stimulation (tACS)

tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.

Sponsors & Collaborators

  • Defense Advanced Research Projects Agency

    collaborator FED

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Emiliano Santarnecchi, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-02
Primary Completion
2019-05-07
Completion
2019-09-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03412604 on ClinicalTrials.gov